Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | COSMIC-313: cabozantinib with nivolumab and ipilimumab in untreated aRCC

Toni Choueiri, MD, Dana Farber Cancer Institute, Boston, MA, discusses the results of the Phase III COSMIC-313 study (NCT03937219), which assessed cabozantinib in combination with nivolumab and ipilimumab in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk. Cabozantinib and nivolumab with ipilimumab significantly improved progression-free survival versus in previously untreated aRCC. Safety was consistent with the known profiles of the treatment components, with follow-up for overall survival currently ongoing. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.